港股異動 | 五菱汽車漲超19%,上汽通用五菱1月銷量超特斯拉兩倍
uSMART盈立智投2月9日消息,週二港股午後,五菱汽車漲幅擴大,截至13:17分,五菱汽車盤中漲超19%,股價最高觸及2.27港元。
2月8日,全國乘用車市場信息聯席會(以下簡稱“乘聯會”)發佈最新銷量數據顯示,1月乘用車市場零售達到216萬輛,同比增長25.7%。
1月新能源乘用車批發銷量達到16.8萬輛,同比增長290.6%,環比12月下降20.5%。
同期,新能源乘用車銷量突破萬輛銷量的企業有5家,分別是上汽通用五菱38496輛、比亞迪20330輛、特斯拉中國15484輛,上汽乘用車14398輛,長城汽車10260輛,並且增速均在三位數以上,其中上汽通用五菱增長達26倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.